An important potential use of the PRS in the clinical setting is for clarifying the genetic background of patients with severe HC, especially individuals that meet the clinical criteria for FH but have no pathogenic variants in the genes responsible for the monogenic form of this condition, namely LDLR, APOB, or PCSK9 (approximately 40% of patients who undergo genetic testing for FH) (Berberich & Hegele, 2019). The gene discussed is PCSK9; the disease is familial hyperaldosteronism.